The Corona Study of Middle Norway (CUT COVID-19)

December 1, 2022 updated by: St. Olavs Hospital

The Middle Norway Corona Study - Individual and Genetic Risk Factors for COVID-19 Infection.

CUT COVID is a cohort study establised to collect information on patients hospitalized because or with infection by SARS-CoV-2. The cohort data includes clinical data and biological samples from multiple timepoints during hospitalization, as well as data from a followup consultation 3 months after discharge.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

223

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Norway
    • MN
      • Trondheim, MN, Norway, 7006
        • St. Olavs Hospital
    • MR
      • Molde, MR, Norway, 6405
        • Molde Hospital
      • Ålesund, MR, Norway, 6017
        • Ålesund Hospital
    • NT
      • Levanger, NT, Norway, 7600
        • Levanger hospital
      • Namsos, NT, Norway, 7800
        • Namsos Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Population of Middle Norway Health Region

Description

Inclusion Criteria:

  • Positive SARS CoV-2 infection

Exclusion Criteria:

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Adult
18+
Other: No intervention
No intervention, cohort study.
Pediatric
Under 18
Other: No intervention
No intervention, cohort study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Predictors of COVID-19 severity
Time Frame: 1 year after inclusion.
Primary aim is to assess predictors of severe COVID disease in children and adults
1 year after inclusion.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

St. Olavs Hospital

Collaborators

The Research Council of Norway
Helse Nord-Trøndelag HF
Alesund Hospital
Namsos Hospital
Molde Hospital

Investigators

  • Principal Investigator: Kari Risnes, MD/PhD, St. Olavs Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2020

Primary Completion (Actual)

December 31, 2021

Study Completion (Actual)

August 12, 2022

Study Registration Dates

First Submitted

November 17, 2022

First Submitted That Met QC Criteria

December 1, 2022

First Posted (Estimate)

December 6, 2022

Study Record Updates

Last Update Posted (Estimate)

December 6, 2022

Last Update Submitted That Met QC Criteria

December 1, 2022

Last Verified

December 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 121891

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

IPD Plan Description

Will be decided on a case-by-case basis dependent on data protection impact assessment.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe